Business Context and Reporting Period
This Form 8-K is filed by Spherix Incorporated (not Dominari Holdings Inc.) on May 16, 2019. The report addresses two primary events: the announcement of operating results for the fiscal quarter ended March 31, 2019, and a restructuring of the terms of a proposed transaction with CBM BioPharma, Inc. (CBM). The company is soliciting proxies from stockholders to approve this proposed transaction.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity for the quarter ended March 31, 2019. It references a press release (Exhibit 99.1) containing these results but does not include the data within the body of this 8-K. The filing directs investors to the Company's Quarterly Report on Form 10-Q (filed May 15, 2019) and Annual Report on Form 10-K (filed March 14, 2019) for detailed financial statements.
Material Changes and Transaction Updates
- Transaction Restructuring: Spherix has restructured the terms of its proposed transaction with CBM BioPharma, Inc.
- Stockholder Action: A special meeting of stockholders will be held to vote on the Proposed Transaction. A definitive proxy statement will be mailed to stockholders.
- Participants: Spherix and CBM, along with their respective directors, executive officers, and management, are deemed participants in the solicitation of proxies.
Guidance, Outlook, and Risks
The filing contains extensive forward-looking statements regarding the likelihood of consummating the transaction and the future benefits of the combined company. Management disclaims any obligation to update these statements. Key risks identified include:
- Failure to obtain required regulatory approvals or stockholder approval.
- Delays in consummating the transaction or integrating CBM's assets.
- Changes in the business environment, including inflation, interest rates, and regulatory conditions.
- Uncertainty regarding the long-term value of Spherix's common stock.
- Failure to realize anticipated benefits of the transaction.
Investor Verification Checklist
- Verify the specific financial results for the quarter ended March 31, 2019, by reviewing the attached Press Release (Exhibit 99.1) or the Form 10-Q filed on May 15, 2019.
- Review the definitive proxy statement for details on the restructured terms of the CBM transaction.
- Confirm the record date and voting procedures for the special stockholder meeting.
- Assess the regulatory approval status required to close the proposed transaction.